BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Concord Drugs Ltd. Share Price

NSE
BSE

BSE : 538965

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

High

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 107.74 432.7
Expenses N/A N/A
PBT 5.21 5.58
Operating profit 0.0 0.0
Net profit 2.22 4.2

Shareholding Pattern

Promoters (% Holding)

54.39%

Mutual funds (% Holding)

0.00%

Non-Institution (% Holding)

45.61%

FI/Banks/Insurance (% Holding)

0.00%

Government (% Holding)

0.00%

FII

0.00%

About Concord Drugs Ltd.

Founded 1995
Managing Director S Nagi Reddy

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,42,725.29 1,845.20 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 1,82,775.12 6,905.00 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,51,764.01 4,494.00 3,102.00 - 3,102.00
Apollo Hospitals Enterprise Ltd. 1,20,200.38 8,361.00 6,696.50 - 6,696.50
Cipla Ltd. 1,13,007.26 1,398.95 1,165.70 - 1,165.70
Dr. Reddy's Laboratories Ltd. 1,09,098.01 1,308.60 1,148.40 - 1,148.40
Zydus Lifesciences Ltd. 1,04,542.68 1,038.95 835.50 - 835.50
Lupin Ltd. 1,04,222.36 2,279.50 1,836.80 - 1,836.80
Mankind Pharma Ltd. 1,02,422.13 2,479.00 1,909.70 - 1,909.70
Max Healthcare Institute Ltd. 99,587.17 1,023.25 903.00 - 903.00
no-content No Records Found

Latest News

May
22
2026
EQUITY Posted on May 22nd 2026

Anuh Pharma informs about newspaper publication

Anuh Pharma has informed that pursuant to the Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, advertisement have been published by the company on Friday, 22nd May, 2026 in Financial Express (English) and Mumbai Lakshdeep (Marathi) Edition pertaining to Audited Financial Results containing a Quick Response Code and the details of the Webpage where the aforesaid complete Financial Results of the Company for the quarter and year ended 31st March, 2026 is accessible. Copies of said publications are enclosed for information and record. This disclosure is being simultaneously uploaded on the website of the company, www.anuhpharma.com
The above information is a part of company’s filings submitted to BSE.
Read More
May
22
2026
EQUITY Posted on May 22nd 2026

Alembic Pharmaceuticals informs about press release

Alembic Pharmaceuticals has informed that the Company has received US Food & Drug Administration (USFDA) Final Approval for Levothyroxine Sodium Tablets USP, 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg and 300 mcg.
The above information is a part of company’s filings submitted to BSE.
Read More
May
22
2026
EQUITY Posted on May 22nd 2026

Sudeep Pharma informs about press release

Sudeep Pharma has informed that it submitted the copies of the extract of audited financials results of the Company for the 4th Quarter and year ended 31st March 2026, published in Business Standard, English Language newspaper and Vadodara Samachar, Regional language newspaper at Vadodara, Gujarat on 22nd May 2026.
The above information is a part of company’s filings submitted to BSE.
Read More
May
22
2026
EQUITY Posted on May 22nd 2026

Lupin informs about press release

Lupin has informed that it enclosed a Press Release titled ‘Lupin Receives China Approval for Oseltamivir Phosphate Oral Suspension’.
The above information is a part of company’s filings submitted to BSE.
Read More
May
22
2026
EQUITY Posted on May 22nd 2026

Krebs Biochemicals and Industries inform about newspaper publication

 Krebs Biochemicals and Industries has informed that it enclosed copies of the Audited Financial Results for the 4th quarter and financial year ended March 31, 2026 approved in the Board Meeting held on May 21, 2026 and published on May 22, 2026 in Business Standard (English) and Prajasakti (Telugu).
The above information is a part of company’s filings submitted to BSE.
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Concord Drugs Ltd. ?

The current share price of Concord Drugs Ltd. is ₹77.74 as of 2026-05-22.

The market capitalisation of Concord Drugs Ltd. is ₹102.42 as of 2026-05-22.

The 1-year return of Concord Drugs Ltd. is 45.77% as of 2026-05-22.

The P/E ratio of Concord Drugs Ltd. is 92.45 as of 2026-05-23.

The 52-week high and low of Concord Drugs Ltd. are ₹92.52 and ₹29.00, respectively, as of 2026-05-22.

The dividend yield of Concord Drugs Ltd. is 0.0% as of2026-05-22.

You can buy Concord Drugs Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Concord Drugs Ltd. is S Nagi Reddy.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore